A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.122.265077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Phillip H Kuo und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona, Tucson, Arizona; pkuo@email.arizona.edu. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
[ 68Ga]Ga-PSMA-11 ( 68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)-positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study.
Methods
In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics.
Results
For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50-0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38-0.71), 0.67 (95% CI, 0.52-0.83), and 0.59 (95% CI, 0.43-0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49-0.99), 0.76 (95% CI, 0.46-0.99), and 0.89 (95% CI, 0.67-0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66-0.85) for reader 1, 70 of 88 (0.80; 0.70-0.87) for reader 2, and 73 of 96 (0.76; 0.66-0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases.
Conclusion
Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Arizona, Tucson, Arizona; pkuo@email.arizona.edu.
- Warren Alpert Medical School of Brown University, Providence, Rhode Island.
- Northwestern University, Evanston, Illinois.
- Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
- Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Zitieren
APA
Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., Brackman, M., Kpamegan, E., Ghebremariam, S., Benson, T., Catafau, A. M., & Kendi, A. T. (2023). A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.265077
Vancouver
Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, et al. A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.122.265077
BibTeX
@article{Kuo2023,
author = {Kuo, Phillip H and Yoo, Don C and Avery, Ryan and Seltzer, Marc and Calais, Jeremie and Nagarajah, James and Weber, Wolfgang A and Fendler, Wolfgang P and Hofman, Michael S and Krause, Bernd J and Brackman, Marcia and Kpamegan, Euloge and Ghebremariam, Samson and Benson, Taylor and Catafau, Ana M and Kendi, Ayse T},
title = {A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.122.265077}
}
EUVIMED